SMARCA2 and thyroid cancer: We observed that the dextral METTL3‐14‐WTAP activator has better activity in promoting redifferentiation of thyroid cancer, as indicated by a more pronounced promotion effect on the mRNA expression of SETMAR, SMARCA2, and thyroid differentiation markers in ATC cells (Figure S11A, Supporting Information), and it more strongly inhibited the viability of ATC cells (Figure S11B, Supporting Information).